Kymera Therapeutics KYMR Issu Issuance Of Common Stock From December Two Thousand Twenty Five Public Offering Net Of Issuance Cost
Issu Issuance Of Common Stock From December Two Thousand Twenty Five Public Offering Net Of Issuance Cost at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept kymr:IssuIssuanceOfCommonStockFromDecemberTwoThousandTwentyFivePublicOfferingNetOfIssuanceCost.
The official record: Kymera Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's issu issuance of common stock from december two thousand twenty five public offering net of issuance cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's issu issuance of common stock from december two thousand twenty five public offering net of issuance cost?
- Kymera Therapeutics (KYMR) reported issu issuance of common stock from december two thousand twenty five public offering net of issuance cost of -$164.06M in Q4 2025.
- What does issu issuance of common stock from december two thousand twenty five public offering net of issuance cost mean?
- Represents the net cash proceeds generated from specific public equity offerings conducted during the designated period. It reflects the company's success in accessing public capital markets to fund research, development, and operational expansion.